The US Food and Drug Administration’s (FDA’s) approval decision about a new treatment for non–muscle invasive bladder cancer (NMIBC) hinges on whether a single-armed trial can be trusted to adequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback